{"id":"https://openalex.org/W4200212421","doi":"https://doi.org/10.1093/ofid/ofab466.1248","title":"1054. Activity of a Anti-staphylococcal Lysin, LSVT-1701: In vitro Susceptibility of Staphylococcus aureus and Coagulase-Negative Staphylococci (CoNS) Global Clinical Isolates (2002 to 2019)","display_name":"1054. Activity of a Anti-staphylococcal Lysin, LSVT-1701: In vitro Susceptibility of Staphylococcus aureus and Coagulase-Negative Staphylococci (CoNS) Global Clinical Isolates (2002 to 2019)","publication_year":2021,"publication_date":"2021-11-01","ids":{"openalex":"https://openalex.org/W4200212421","doi":"https://doi.org/10.1093/ofid/ofab466.1248"},"language":"en","primary_location":{"id":"doi:10.1093/ofid/ofab466.1248","doi":"https://doi.org/10.1093/ofid/ofab466.1248","is_oa":true,"landing_page_url":"https://doi.org/10.1093/ofid/ofab466.1248","pdf_url":null,"source":{"id":"https://openalex.org/S2735126445","display_name":"Open Forum Infectious Diseases","issn_l":"2328-8957","issn":["2328-8957"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","dongbi-c","doyens","jufo-1","ki-jl-1","norway-1","poland-100","russia-white-list-2","vabb-shw"],"host_organization":"https://openalex.org/P4310311648","host_organization_name":"Oxford University Press","host_organization_lineage":["https://openalex.org/P4310311648","https://openalex.org/P4310311647"],"host_organization_lineage_names":["Oxford University Press","University of Oxford"],"type":"journal"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Open Forum Infectious Diseases","raw_type":"journal-article"},"volume":null,"type":"article","indexed_in":["crossref","doaj"],"open_access":{"is_oa":true,"oa_status":"gold","oa_url":"https://doi.org/10.1093/ofid/ofab466.1248","any_repository_has_fulltext":true},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5016570350","display_name":"David B. Huang","orcid":"https://orcid.org/0000-0001-8228-7911","observed_orcids":["https://orcid.org/0000-0001-8228-7911","https://orcid.org/0000-0002-8342-3193"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"David Huang","raw_affiliation_strings":["Lysovant, Houston, Texas"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Lysovant, Houston, Texas","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5089371529","display_name":"Helio Silva Sader","orcid":"https://orcid.org/0000-0001-7022-6644","observed_orcids":["https://orcid.org/0000-0001-7022-6644"]},"institutions":[{"id":"https://openalex.org/I4210121169","display_name":"JMI Laboratories","ror":"https://ror.org/02qv6pw23","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210121169"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Helio S Sader","raw_affiliation_strings":["JMI Laboratories, North Liberty, Iowa"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"JMI Laboratories, North Liberty, Iowa","institution_ids":["https://openalex.org/I4210121169"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5073303672","display_name":"Paul R. Rhomberg","orcid":"https://orcid.org/0000-0001-6798-7653","observed_orcids":["https://orcid.org/0000-0001-6798-7653"]},"institutions":[{"id":"https://openalex.org/I4210121169","display_name":"JMI Laboratories","ror":"https://ror.org/02qv6pw23","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210121169"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Paul R Rhomberg","raw_affiliation_strings":["JMI Laboratories, North Liberty, Iowa"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"JMI Laboratories, North Liberty, Iowa","institution_ids":["https://openalex.org/I4210121169"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5010901896","display_name":"Katyna Borroto\u2013Esoda","orcid":"https://orcid.org/0000-0002-3909-6578","observed_orcids":["https://orcid.org/0000-0002-3909-6578"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Katyna Borroto-Esoda","raw_affiliation_strings":["Lysovant, Houston, Texas"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Lysovant, Houston, Texas","institution_ids":[]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5046134687","display_name":"Eric J. Gaukel","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Eric Gaukel","raw_affiliation_strings":["Lysovant, Houston, Texas"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Lysovant, Houston, Texas","institution_ids":[]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":1,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":{"value":3465,"currency":"USD","value_usd":3465},"apc_paid":{"value":3465,"currency":"USD","value_usd":3465},"fwci":0.0,"has_fulltext":false,"cited_by_count":0,"citation_normalized_percentile":{"value":0.22810547,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":null,"biblio":{"volume":"8","issue":"Supplement_1","first_page":"S618","last_page":"S619"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10195","display_name":"Antimicrobial Resistance in Staphylococcus","score":0.9707000255584717,"subfield":{"id":"https://openalex.org/subfields/2725","display_name":"Infectious Diseases"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10195","display_name":"Antimicrobial Resistance in Staphylococcus","score":0.9707000255584717,"subfield":{"id":"https://openalex.org/subfields/2725","display_name":"Infectious Diseases"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11048","display_name":"Bacteriophages and microbial interactions","score":0.027400000020861626,"subfield":{"id":"https://openalex.org/subfields/2303","display_name":"Ecology"},"field":{"id":"https://openalex.org/fields/23","display_name":"Environmental Science"},"domain":{"id":"https://openalex.org/domains/3","display_name":"Physical Sciences"}},{"id":"https://openalex.org/T12526","display_name":"Antimicrobial agents and applications","score":0.00019999999494757503,"subfield":{"id":"https://openalex.org/subfields/1605","display_name":"Organic Chemistry"},"field":{"id":"https://openalex.org/fields/16","display_name":"Chemistry"},"domain":{"id":"https://openalex.org/domains/3","display_name":"Physical Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/staphylococcus-aureus","display_name":"Staphylococcus aureus","score":0.9279999732971191},{"id":"https://openalex.org/keywords/coagulase-negative-staphylococci","display_name":"coagulase-negative staphylococci","score":1.0},{"id":"https://openalex.org/keywords/antimicrobial-susceptibility","display_name":"antimicrobial susceptibility","score":0.7879999876022339},{"id":"https://openalex.org/keywords/minimum-inhibitory-concentration","display_name":"minimum inhibitory concentration","score":0.734000027179718},{"id":"https://openalex.org/keywords/methicillin-resistant-staphylococcus-aureus","display_name":"methicillin-resistant Staphylococcus aureus","score":0.6309999823570251},{"id":"https://openalex.org/keywords/methicillin-susceptible-staphylococcus-aureus","display_name":"methicillin-susceptible Staphylococcus aureus","score":0.8399999737739563},{"id":"https://openalex.org/keywords/oxacillin-resistance","display_name":"oxacillin resistance","score":0.8069999814033508},{"id":"https://openalex.org/keywords/vancomycin-resistance","display_name":"vancomycin resistance","score":0.7670000195503235},{"id":"https://openalex.org/keywords/teicoplanin-resistance","display_name":"teicoplanin resistance","score":0.8050000071525574},{"id":"https://openalex.org/keywords/linezolid-resistance","display_name":"linezolid resistance","score":0.8759999871253967},{"id":"https://openalex.org/keywords/daptomycin-resistance","display_name":"daptomycin resistance","score":0.9559999704360962},{"id":"https://openalex.org/keywords/staphylococcal-infections","display_name":"staphylococcal infections","score":0.6140000224113464},{"id":"https://openalex.org/keywords/clinical-isolates","display_name":"clinical isolates","score":0.5419999957084656}],"concepts":[{"id":"https://openalex.org/C89423630","wikidata":"https://www.wikidata.org/wiki/Q7193","display_name":"Microbiology","level":1,"score":0.7074204683303833},{"id":"https://openalex.org/C2779489039","wikidata":"https://www.wikidata.org/wiki/Q188121","display_name":"Staphylococcus aureus","level":3,"score":0.7015765309333801},{"id":"https://openalex.org/C2776703206","wikidata":"https://www.wikidata.org/wiki/Q2731762","display_name":"Teicoplanin","level":5,"score":0.6316837072372437},{"id":"https://openalex.org/C2781414143","wikidata":"https://www.wikidata.org/wiki/Q411377","display_name":"Linezolid","level":5,"score":0.6030226349830627},{"id":"https://openalex.org/C2780950330","wikidata":"https://www.wikidata.org/wiki/Q19903614","display_name":"Broth microdilution","level":4,"score":0.6011646389961243},{"id":"https://openalex.org/C8408860","wikidata":"https://www.wikidata.org/wiki/Q1755077","display_name":"Coagulase","level":5,"score":0.5573722124099731},{"id":"https://openalex.org/C37091826","wikidata":"https://www.wikidata.org/wiki/Q3687178","display_name":"cons","level":2,"score":0.5207493305206299},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.5101621150970459},{"id":"https://openalex.org/C2778980435","wikidata":"https://www.wikidata.org/wiki/Q424027","display_name":"Vancomycin","level":4,"score":0.49920153617858887},{"id":"https://openalex.org/C86803240","wikidata":"https://www.wikidata.org/wiki/Q420","display_name":"Biology","level":0,"score":0.33076247572898865},{"id":"https://openalex.org/C2779288629","wikidata":"https://www.wikidata.org/wiki/Q199695","display_name":"Staphylococcus","level":4,"score":0.2882174253463745},{"id":"https://openalex.org/C501593827","wikidata":"https://www.wikidata.org/wiki/Q12187","display_name":"Antibiotics","level":2,"score":0.2477550506591797},{"id":"https://openalex.org/C176947019","wikidata":"https://www.wikidata.org/wiki/Q597889","display_name":"Minimum inhibitory concentration","level":3,"score":0.21820032596588135},{"id":"https://openalex.org/C523546767","wikidata":"https://www.wikidata.org/wiki/Q10876","display_name":"Bacteria","level":2,"score":0.10799390077590942},{"id":"https://openalex.org/C199360897","wikidata":"https://www.wikidata.org/wiki/Q9143","display_name":"Programming language","level":1,"score":0.0},{"id":"https://openalex.org/C41008148","wikidata":"https://www.wikidata.org/wiki/Q21198","display_name":"Computer science","level":0,"score":0.0},{"id":"https://openalex.org/C54355233","wikidata":"https://www.wikidata.org/wiki/Q7162","display_name":"Genetics","level":1,"score":0.0}],"mesh":[],"locations_count":2,"locations":[{"id":"doi:10.1093/ofid/ofab466.1248","doi":"https://doi.org/10.1093/ofid/ofab466.1248","is_oa":true,"landing_page_url":"https://doi.org/10.1093/ofid/ofab466.1248","pdf_url":null,"source":{"id":"https://openalex.org/S2735126445","display_name":"Open Forum Infectious Diseases","issn_l":"2328-8957","issn":["2328-8957"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","dongbi-c","doyens","jufo-1","ki-jl-1","norway-1","poland-100","russia-white-list-2","vabb-shw"],"host_organization":"https://openalex.org/P4310311648","host_organization_name":"Oxford University Press","host_organization_lineage":["https://openalex.org/P4310311648","https://openalex.org/P4310311647"],"host_organization_lineage_names":["Oxford University Press","University of Oxford"],"type":"journal"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Open Forum Infectious Diseases","raw_type":"journal-article"},{"id":"pmh:oai:pubmedcentral.nih.gov:8644221","doi":null,"is_oa":true,"landing_page_url":"https://www.ncbi.nlm.nih.gov/pmc/articles/8644221","pdf_url":null,"source":{"id":"https://openalex.org/S2764455111","display_name":"PubMed Central","issn_l":null,"issn":null,"is_oa":true,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Open Forum Infect Dis","raw_type":"Text"}],"best_oa_location":{"id":"doi:10.1093/ofid/ofab466.1248","doi":"https://doi.org/10.1093/ofid/ofab466.1248","is_oa":true,"landing_page_url":"https://doi.org/10.1093/ofid/ofab466.1248","pdf_url":null,"source":{"id":"https://openalex.org/S2735126445","display_name":"Open Forum Infectious Diseases","issn_l":"2328-8957","issn":["2328-8957"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","dongbi-c","doyens","jufo-1","ki-jl-1","norway-1","poland-100","russia-white-list-2","vabb-shw"],"host_organization":"https://openalex.org/P4310311648","host_organization_name":"Oxford University Press","host_organization_lineage":["https://openalex.org/P4310311648","https://openalex.org/P4310311647"],"host_organization_lineage_names":["Oxford University Press","University of Oxford"],"type":"journal"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Open Forum Infectious Diseases","raw_type":"journal-article"},"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","score":0.9476000070571899,"display_name":"Good health and well-being"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W3176771986","https://openalex.org/W1582291275","https://openalex.org/W2761988201","https://openalex.org/W2116017699","https://openalex.org/W2187520155","https://openalex.org/W2098057103","https://openalex.org/W2379549886","https://openalex.org/W7158494877","https://openalex.org/W2050899092","https://openalex.org/W2170797416"],"abstract_inverted_index":{"Abstract":[0],"Background":[1],"LSVT-1701,":[2],"formerly":[3],"SAL200,":[4],"is":[5],"a":[6],"novel,":[7],"recombinantly-produced,":[8],"bacteriophage-encoded":[9],"lysin":[10],"that":[11],"specifically":[12],"targets":[13],"staphylococci":[14,36],"via":[15],"cell":[16],"wall":[17],"enzymatic":[18],"hydrolysis.":[19],"We":[20],"reported":[21],"the":[22,71,113,122],"in":[23,64,70,246],"vitro":[24,247],"activity":[25,189,234,248],"of":[26,31,152,232,253,275,282,326],"LSVT-1701":[27,41,139,172,186,233,243,283],"against":[28,46,143,190,235,249,264],"clinical":[29,54,251,280],"isolates":[30,55,61,109,117,148,193,252,268],"S.":[32,48,144,157,160,164,181,191,227,236,254,266,296],"aureus":[33,49,145,161,165,182,192,228,255,267],"and":[34,42,51,98,133,146,167,177,183,217,239,256,263,328],"coagulase-negative":[35],"(CoNS)":[37],"collected":[38,63,258],"worldwide.":[39],"Methods":[40],"comparators":[43],"were":[44,62,118,129,175],"tested":[45,120],"415":[47],"(n=315)":[50],"CoNS":[52,147,168,238,257],"(n=100)":[53],"expressing":[56],"various":[57],"resistance":[58,195,271],"phenotypes.":[59,272],"The":[60,170,273],"2002-2019":[65],"from":[66,112,212,221,259],"medical":[67,75,83,92,102,260],"centers":[68,261],"located":[69],"United":[72],"States":[73],"(50":[74],"centers;":[76,84,93,103],"174":[77],"isolates;":[78,86,95,105],"41.9%":[79],"overall),":[80,88,97],"Europe":[81],"(37":[82],"140":[85],"33.7%":[87],"Asia-Pacific":[89],"region":[90],"(15":[91],"55":[94],"13.3%":[96],"Latin":[99],"America":[100],"(12":[101],"46":[104],"11.1%":[106],"overall).":[107],"These":[108],"originated":[110],"mostly":[111],"year":[114],"2019":[115],"(n=323).The":[116],"susceptibility":[119,198],"by":[121],"CLSI":[123,132],"broth":[124],"microdilution":[125],"method.":[126],"MIC":[127,173],"interpretations":[128],"based":[130],"on":[131],"EUCAST":[134],"criteria":[135],"where":[136],"available.":[137],"Results":[138],"was":[140],"highly":[141],"active":[142],"with":[149,269],"MIC90":[150,218],"values":[151,174,210,219],"2":[153],"mg/L":[154,179,216,225],"for":[155],"all":[156],"aureus,":[158,237],"methicillin-susceptible":[159],"(MSSA),":[162],"methicillin-resistant":[163],"(MRSA),":[166],"(Table).":[169],"highest":[171],"4":[176,224],"8":[178],"among":[180,226],"CoNS,":[184],"respectively.":[185],"retained":[187],"potent":[188,245],"showing":[194],"or":[196,207,306,313,318,324,333,342,347,352,356,361,371,376],"decreased":[197],"to":[199,214,223,284],"oxacillin,":[200],"vancomycin,":[201],"teicoplanin,":[202],"telavancin,":[203],"linezolid,":[204],"daptomycin,":[205],"ceftaroline,":[206],"lefamulin;":[208],"MIC50":[209],"ranged":[211,220],"0.5":[213],"1":[215,222],"resistant":[229,240,265],"subsets.":[230],"Summary":[231],"subsets":[241],"Conclusion":[242],"demonstrated":[244],"contemporary":[250],"worldwide":[262],"uncommon":[270],"results":[274],"this":[276],"study":[277],"support":[278],"further":[279],"development":[281],"treat":[285],"staphylococcal":[286],"infections.":[287],"Disclosures":[288],"David":[289],"Huang,":[290],"MD,":[291,298],"PhD,":[292,299,380],"Lysovant":[293,381,386],"(Consultant)":[294,382],"Helio":[295],"Sader,":[297],"FIDSA,":[300],"AbbVie":[301],"(formerly":[302],"Allergan)":[303],"(Research":[304,311,316,322,331,340,345,350,354,359,369,374],"Grant":[305,312,317,323,332,341,346,351,355,360,370,375],"Support)Basilea":[307],"Pharmaceutica":[308],"International,":[309],"Ltd.":[310],"Support)Cipla":[314,319],"Therapeutics":[315,344,358],"USA":[320],"Inc.":[321,349,368,373],"Support)Department":[325],"Health":[327],"Human":[329],"Services":[330],"Support,":[334],"Contract":[335],"no.":[336],"HHSO100201600002C)Melinta":[337],"Therapeutics,":[338,367],"LLC":[339],"Support)Nabriva":[343],"Support)Pfizer,":[348,372],"Support)Shionogi":[353],"Support)Spero":[357],"Support)":[362,377],"Paul":[363],"R":[364],"Rhomberg,":[365],"Cidara":[366],"Katyna":[378],"Borroto-Esoda,":[379],"Eric":[383],"Gaukel,":[384],"BS,":[385],"(Employee)":[387]},"counts_by_year":[],"updated_date":"2026-10-27T15:51:10.671819","created_date":"2021-12-31T00:00:00"}